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Efficacy and safety of statin therapy in older people: 
a meta-analysis of individual participant data from 
28 randomised controlled trials 
Cholesterol Treatment Trialists’ Collaboration*
Summary
Background Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of 
individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis 
of data from all large statin trials to compare the effects of statin therapy at different ages.
Methods In this meta-analysis, randomised trials of statin therapy were eligible if they aimed to recruit at least 
1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data 
from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, 
plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). 
We subdivided participants into six age groups (55 years or younger, 56–60 years, 61–65 years, 66–70 years, 
71–75 years, and older than 75 years). We estimated effects on major vascular events (ie, major coronary events, 
strokes, and coronary revascularisations), cause-specific mortality, and cancer incidence as the rate ratio (RR) 
per 1·0 mmol/L reduction in LDL cholesterol. We compared proportional risk reductions in different age 
subgroups by use of standard χ² tests for heterogeneity when there were two groups, or trend when there were 
more than two groups.
Findings 14 483 (8%) of 186 854 participants in the 28 trials were older than 75 years at randomisation, and the 
median follow-up duration was 4·9 years. Overall, statin therapy or a more intensive statin regimen produced a 
21% (RR 0·79, 95% CI 0·77–0·81) proportional reduction in major vascular events per 1·0 mmol/L reduction in 
LDL cholesterol. We observed a significant reduction in major vascular events in all age groups. Although 
proportional reductions in major vascular events diminished slightly with age, this trend was not statistically 
significant (ptrend=0·06). Overall, statin or more intensive therapy yielded a 24% (RR 0·76, 95% CI 0·73–0·79) 
proportional reduction in major coronary events per 1·0 mmol/L reduction in LDL cholesterol, and with increasing 
age, we observed a trend towards smaller proportional risk reductions in major coronary events (ptrend=0·009). We 
observed a 25% (RR 0·75, 95% CI 0·73–0·78) proportional reduction in the risk of coronary revascularisation 
procedures with statin therapy or a more intensive statin regimen per 1·0 mmol/L lower LDL cholesterol, which 
did not differ significantly across age groups (ptrend=0·6). Similarly, the proportional reductions in stroke of any 
type (RR 0·84, 95% CI 0·80–0·89) did not differ significantly across age groups (ptrend=0·7). After exclusion of 
four trials which enrolled only patients with heart failure or undergoing renal dialysis (among whom statin therapy 
has not been shown to be effective), the trend to smaller proportional risk reductions with increasing age persisted 
for major coronary events (ptrend=0·01), and remained non-significant for major vascular events (ptrend=0·3). 
The proportional reduction in major vascular events was similar, irrespective of age, among patients with 
pre-existing vascular disease (ptrend=0·2), but appeared smaller among older than among younger individuals 
not known to have vascular disease (ptrend=0·05). We found a 12% (RR 0·88, 95% CI 0·85–0·91) proportional 
reduction in vascular mortality per 1·0 mmol/L reduction in LDL cholesterol, with a trend towards smaller 
proportional reductions with older age (ptrend=0·004), but this trend did not persist after exclusion of the heart 
failure or dialysis trials (ptrend=0·2). Statin therapy had no effect at any age on non-vascular mortality, cancer death, 
or cancer incidence.
Interpretation Statin therapy produces significant reductions in major vascular events irrespective of age, but there is 
less direct evidence of benefit among patients older than 75 years who do not already have evidence of occlusive 
vascular disease. This limitation is now being addressed by further trials.
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Biomedical Research Centre, UK Medical Research Council, and British Heart Foundation.
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4.0 license.
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Introduction
Meta-analyses of individual participant data from 
27 randomised trials in the Cholesterol Treatment 
Trialists’ (CTT) Collaboration database indicate that each 
1·0 mmol/L reduction in LDL cholesterol with statin 
therapy reduces the risk of major vascular events by 
about a fifth, with similar proportional risk reductions 
among men and women,1 and across different levels of 
absolute risk.2 However, even among patients with 
established cardiovascular disease, rates of use of statin 
therapy have been shown to decline with increasing 
age, and are substantially lower in people older than 
75 years, reflecting differences in both prescribing and 
compliance.3,4 This decline is even more prominent 
among older patients with no evidence of occlusive 
vascular disease.5 One explanation for this observation 
might relate to uncertainty about applying the evidence 
for statin efficacy and safety from randomised trials to an 
older population, given that a relatively small number 
of people aged over 75 years were enrolled in such 
trials, and many older people have non-cardiovascular 
comorbidities.6–10 The CTT collaboration has age-specific 
data on vascular events, cause-specific mortality, and 
cancer from 28 randomised controlled trials of statin 
therapy among a total of nearly 187 000 participants, of 
whom about 14 500 were older than 75 years at baseline. 
We aimed to do a meta-analysis of data from all large 
statin trials to compare the effects of statin therapy at 
different ages and explore the effects of statin therapy 
among older individuals.
Methods
Study design and outcomes
The methods of the CTT Collaboration have been 
described previously,11 and were agreed before the 
reporting of any individual trial results. Randomised trials 
were eligible for inclusion if the main effect of at least one 
of the trial interventions was to lower LDL cholesterol, the 
trial was unconfounded with respect to this intervention 
(ie, no other differences in modification of risk factors 
between the relevant treatment groups were intended), 
and the trial aimed to recruit 1000 or more participants 
with a scheduled treatment duration of at least 2 years.11
As for all CTT analyses,1,2,11–16 the risk of bias was low 
because of prespecified study methods, the ability to 
adjust for heterogeneity by weighting rate ratios (RRs) 
according to trial-level absolute differences in LDL 
cholesterol, and the low probability of publication bias due 
to a prospective design with prespecified study eligibility. 
Prespecified outcomes included major coron ary events 
(defined as non-fatal myocardial infarc tion or coronary 
death), coronary revascularisation (angio plasty or by pass 
Research in context
Evidence before this study
Before this meta-analysis, the evidence available from 
randomised trials on the effects of statin therapy in older 
people had been summarised only in meta-analyses of 
aggregated data from published reports. We searched 
MEDLINE, Embase, and PubMed for English-language 
publications published between Jan 1, 1996, and 
Dec 31, 2017, using the search terms “statins OR HMG CoA 
Reductase Inhibitors” and “Elderly OR Aged”, and found 
14 meta-analyses with conflicting assessments of efficacy 
among older people (generally defined as >65 years). Because 
of a lack of access to the individual participant data, none of 
these previous meta-analyses were able to examine the 
effects of statins within particular older age groups 
(eg, >75 years) in primary and secondary prevention. 
We previously reported meta-analyses of the effects of 
statins by age, but these analyses were restricted in scope 
and some large randomised trials that included older 
individuals have been reported since they were published.
Added value of this study
We analysed individual participant data from 27 randomised 
controlled trials (n=174 149) and detailed summary data from 
one trial (n=12 705). During 4·9 years of follow-up, major 
vascular events were significantly reduced by statin therapy 
among all age groups by about a fifth per 1·0 mmol/L LDL 
cholesterol reduction, including among the 14 483 participants 
who were older than 75 years at randomisation. Older age 
groups were disproportionately represented in heart failure 
and dialysis trials (which did not show an overall benefit with 
statin therapy), and exclusion of those trials weakened an 
apparent trend with increasing age towards smaller relative 
risk reductions in vascular event and mortality outcomes. We 
found significant reductions in major coronary events in all age 
groups (including those older than 75 years at randomisation), 
but the trend towards smaller relative reductions with 
increasing age persisted, even after excluding heart failure and 
dialysis trials. However, as the absolute risk of these events was 
higher in older people, the absolute benefits were similar to, if 
not greater than, those at younger ages. We observed 
significant efficacy regardless of age among participants with 
previous vascular disease, whereas there was a weak trend 
towards smaller relative risk reductions with increasing age in 
the primary prevention setting (although there were too few 
such older participants for reliable assessment in that group 
alone). Despite previous concerns, we found no adverse effects 
on cancer or non-vascular mortality in any age group.
Implications of all the available evidence
Statins reduced vascular events irrespective of age, including in 
people older than 75 years. In the primary prevention setting, 
among people older than 75 years, there is less evidence of the 
effects of statin therapy. Ongoing trials are investigating this 
group directly.
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grafting), stroke (subdivided by type), site-specific cancers, 
and cause-specific mortality. Sub sequently, we defined 
major vascular events as the com posite of major coronary 
events, coronary revascu larisation, and stroke.
Statistical analysis
Prespecified subgroup analyses included comparisons of 
the effects of statin therapy among people aged 65 years 
and younger and people older than 65 years at 
randomisation (along with several other subgroupings, 
including by history of vascular disease11). However, for 
the present more detailed analysis, we compared effects 
between six age groups (55 years or younger, 56–60 years, 
61–65 years, 66–70 years, 71–75 years, and older than 
75 years) and, where statistical power was limited because 
of low numbers of specific event types, between two 
retrospectively defined groups (≤75 years and >75 years). 
Because of disproportionate representation of older 
people (particularly >75 years) in four trials done 
exclusively among people with heart failure17,18 or receiving 
renal dialysis,19,20 for whom statin therapy shows little or 
no benefit, we also examined the effects after exclusion of 
these trials.
Analyses included all randomised patients, irrespective 
of whether they received their allocated treatment 
(intention to treat). Estimates of the effects on disease 
rates within each trial were derived from the log-rank 
(o – e) statistic and its variance (v) for first events. Meta-
analyses were weighted by the absolute LDL cholesterol 
difference in that trial at 1 year (d mmol/L), and are 
reported as effects per 1·0 mmol/L reduction in LDL 
cholesterol.1,2,12–16 In a meta-analysis of several trials, the 
log of the RR per 1·0 mmol/L was then calculated as S/V 
with variance 1/V (and hence, for example, with 95% CI 
of S/V ± 1·96 ÷ √V), where S is the sum over all trials of 
d(o – e) and V is the sum over all trials of d²v. We 
compared proportional risk reductions in different age 
subgroups by use of standard χ² tests for heterogeneity 
when there were two groups, or trend when there were 
more than two groups.
To allow for multiple subdivisions of the data into 
subgroups, we present only summary RRs with 95% CIs; 
≤75 years  
(n=172 321)
>75 years 
(n=14 483)
Age (years) 61·6 (8·0) 78·8 (2·8)
Sex
Male 125 783 (73%) 8476 (59%)
Female 46 538 (27%) 6007 (41%)
History of vascular disease 96 088 (56%) 8034 (55%)
History of myocardial 
infarction
59 654 (35%) 4210 (29%)
History of other 
symptomatic coronary 
heart disease
61 767 (36%) 4448 (31%)
History of heart failure 
(New York Heart 
Association class II–IV)*
6692 (4%) 2893 (20%)
On dialysis† 3546 (2%) 482 (3%)
History of diabetes 31 919 (19%) 2499 (17%)
Current smoker 35 701 (21%) 1485 (10%)
Treated hypertension 82 213 (48%) 8696 (60%)
Systolic blood pressure 
(mm Hg)
138·1 (19·5) 143·4 (21·4)
Diastolic blood pressure 
(mm Hg)
81·2 (10·6) 78·9 (10·8)
Body–mass index (kg/m²) 27·1 (24·6–30·1) 26·3 (23·8–29·1)
Total cholesterol (mmol/L) 5·4 (1·0) 5·1 (1·0)
LDL cholesterol (mmol/L) 3·3 (0·9) 3·2 (0·8)
HDL cholesterol (mmol/L) 1·2 (0·3) 1·3 (0·3)
Triglycerides (mmol/L) 1·6 (1·2–2·2) 1·4 (1·0–1·9)
Creatinine (µmol/L)‡ 94 (80–106) 99 (88–117)
Data are mean SD, n (%), or median (IQR). HOPE-3 participant data for body-mass 
index (mean 27·2 kg/m² [SD 4·8] among participants ≤75 years and 26·1 kg/m² [4·8] 
among participants >75 years), triglycerides (1·7 mmol/L [1·1] among participants 
≤75 years and 1·6 mmol/L [0·9] among participants >75 years), and creatinine 
(79 μmol/L [19] among participants ≤75 years and 82 μmol/L [20] among 
participants >75 years) not included. 50 participants with missing age (49 from 
MEGA and one from A to Z) were excluded. *All participants from GISSI-HF and 
CORONA trials only. †All participants from 4D and AURORA trials. ‡Excludes 
participants on dialysis at randomisation (ie, participants from 4D and AURORA).
Table: Baseline characteristics
Figure 1: Effects on major vascular events per mmol/L reduction in LDL cholesterol by age at randomisation
All studies (A) and excluding four trials that exclusively included patients with heart failure or on dialysis (B). 
Data from participants with missing baseline data included in the totals. RR=rate ratio.
Events (% per annum) RR (CI) per 
1 mmol/L 
reduction 
in LDL 
cholesterol
Statin or 
more intensive
Control or 
less intensive
≤55 years
>55 to ≤60 years
>60 to ≤65 years
>65 to ≤70 years
>70 to ≤75 years
>75 years
Total
Trend test χ21=3·56 (p=0·06)
2217 (2·7%)
1741 (2·6%)
2238 (2·8%)
2263 (3·0%)
1993 (3·8%)
1051 (4·5%)
11  503 (3·0%)
2778 (3·4%)
2107 (3·2%)
2723 (3·5%)
2867 (3·9%)
2339 (4·5%)
1153 (5·0%)
13 967 (3·7%)
0·75 (0·70–0·81)
0·80 (0·74–0·87)
0·80 (0·74–0·86)
0·76 (0·71–0·82)
0·81 (0·74–0·88)
0·87 (0·77–0·99)
0·79 (0·77–0·81)
99% CI 95% CI
A
≤55 years
>55 to ≤60 years
>60 to ≤65 years
>65 to ≤70 years
>70 to ≤75 years
>75 years
Total
Trend test χ21=0·98 (p=0·3)
2129 (2·7%)
1637 (2·5%)
2083 (2·7%)
2065 (2·9%)
1802 (3·7%)
802 (4·1%)
10 518 (2·9%)
 2680 (3·4%)
 2018 (3·2%)
 2549 (3·4%)
 2666 (3·8%)
 2134 (4·5%)
 893 (4·7%)
12 940 (3·7%)
0·75 (0·69–0·81)
0·78 (0·72–0·85)
0·79 (0·74–0·86)
0·74 (0·69–0·80)
0·80 (0·73–0·87)
0·82 (0·70–0·95)
0·77 (0·75–0·79)
0·5
99% CI
0·75 1·51
95% CI
Statin or more 
intensive better
Control or less 
intensive better
B
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all other RRs are presented with 99% CIs. All analyses 
were done with SAS (version 9.3) and R (version 3.2.5).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The writing committee had full 
access to all the data in the study and takes final 
responsibility for its content and the decision to submit 
for publication.
Results
Individual participant data were provided by investi-
gators or sponsors for 27 trials of statin therapy,2 and 
detailed summary data provided for one further trial,21 
permitting meta-analyses of all 28 trials. Data were 
unavailable for four eligible trials (9264 participants), 
all of which ex clusively enrolled people with known 
vascular disease.22–25
In 23 trials, a statin-based regimen was compared with 
placebo or usual care (147 242 participants; median follow-
up 4·8 years). In the other five trials, an intensive statin 
regimen was assessed against a standard statin regimen 
(39 612 par tici pants; median follow-up 5·1 years).1 Across 
all 28 trials, the median follow-up duration was 4·9 years 
(range 2·0 to 7·0). 39 242 (21%) of 186 854 partici pants 
were aged 55 years or younger, 31 434 (17%) were 
56–60 years, 37 764 (20%) were 61–65 years, 36 567 (20%) 
were 66–70 years, 27 314 (15%) were aged 71–75 years, and 
14 483 (8%) were older than 75 years (appendix; age was 
unrecorded for 50 par ticipants, none of whom had a major 
vascular event, died, or developed cancer during the trial).
We found significant differences in each of the 
measured baseline characteristics across the six age 
groups (p<0·001 for all comparisons; appendix). Older 
participants were more likely to be female and to have 
heart failure or hypertension and were less likely to be 
current smokers. 2893 (20%) of patients older than 
75 years compared with 6692 (4%) of those aged 75 years 
or younger were patients in heart failure trials, and 
482 (3%) of patients older than 75 years compared with 
3546 (2%) of those aged 75 years or younger were patients 
in renal dialysis trials (table). We observed a trend 
towards lower baseline LDL cholesterol concentrations 
with increasing age in the statin therapy versus control 
trials and—to a lesser extent—in the more intensive 
versus standard statin trials (appendix). Mean LDL 
cholesterol differences between treatment arms at one 
year (overall difference 1·08 mmol/L) were slightly 
smaller among older participants (appendix).
Among all 28 trials, statin therapy or a more intensive 
statin regimen compared with control therapy or a less 
intensive statin regimen produced a 21% (RR 0·79, 
95% CI 0·77–0·81) proportional reduction in the risk of a 
first major vascular event per 1·0 mmol/L reduction in 
LDL cholesterol. We found independently significant risk 
reductions in each of the age groups considered, 
including among patients older than 75 years at the start 
of treatment (figure 1). Although proportional reductions 
in major vascular events diminished slightly with 
increasing age, this trend was not statistically significant 
(ptrend=0·06; figure 1). Previous studies have found that 
statin therapy does not reduce the rate of major vascular 
events among patients with moderate or severe heart 
failure or who are undergoing dialysis for renal failure16–20 
(pheterogeneity<0·0001; figure 2). A dispro portionate number 
of patients with heart failure or dialysis were in the older 
age groups of our overall meta-analysis population, which 
could confound comparisons between the effects of statin 
therapy by age. In exploratory analyses, after exclusion of 
13 613 (7%) patients from four trials restricted to patients 
with heart failure or undergoing dialysis,17–20 the non-
significant trend towards smaller proportional reductions 
in major vascular events with increasing age was 
diminished (ptrend=0·3; figure 1). These patterns were 
unchanged after adjustment for sex, diabetes, 
hypertension, smoking, previous cardiovascular disease 
status, body–mass index (BMI), and renal function 
(adjusted ptrend=0·06 in 27 trials with individual participant 
data; p=0·4 after exclusion of four trials that exclusively 
included participants with heart failure or on dialysis).
Overall, statin or more intensive therapy yielded a 
24% (RR 0·76, 95% CI 0·73–0·79) proportional 
Figure 2: Effects on major vascular events per mmol/L reduction in LDL cholesterol, subdivided by age at 
randomisation and particular trial populations
Data from participants with missing baseline data included in the totals. RR=rate ratio.
Events (% per annum) RR (CI) per 
1 mmol/L 
reduction in 
LDL cholesterol
Statin or 
more intensive
Control or 
less intensive
≤75 years
Heart failure trials
Dialysis trials
Other trials
Subtotal
Heterogeneity test χ21=14·51 (p=0·0001)
>75 years
Heart failure trials
Dialysis trials
Other trials
Subtotal
Heterogeneity test χ21=3·37 (p=0·07)
All participants
Heart failure trials
Dialysis trials
Other trials
Total
Heterogeneity test χ21=21·01 (p<0·0001)
 304 (3·0)
432 (7·9)
9716 (2·9)
10 452 (2·9)
175 (4·8)
74 (12·8)
802 (4·1)
 1051 (4·5)
479 (3·5)
 506 (8·3)
10  518 (2·9)
11 503 (3·0)
308 (3·1)
459 (8·5)
12 047 (3·6)
12 814 (3·7)
189 (5·1)
71 (11·4)
 893 (4·7)
1153 (5·0)
497 (3·6)
530 (8·8)
12 940 (3·7)
13 967 (3·7)
0·96 (0·79–1·16)
0·93 (0·78–1·11)
0·77 (0·74–0·80)
0·78 (0·76–0·80)
0·95 (0·75–1·22)
1·10 (0·71–1·71)
0·82 (0·70–0·95)
0·87 (0·79–0·96)
0·95 (0·82–1·11)
0·95 (0·81–1·12)
0·77 (0·75–0·80)
0·79 (0·77–0·81)
0·5
99% CI
0·75 1·51
95% CI
Statin or more 
intensive better
Control or less 
intensive better
See Online for appendix
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reduction in major coronary events per 1·0 mmol/L 
reduction in LDL cholesterol. We found a statistically 
significant trend towards smaller proportional 
reductions in major coronary events with increasing 
age (ptrend=0·009; figure 3), which remained significant 
after exclusion of the heart failure and dialysis trials 
(ptrend=0·01; appendix). These patterns were unchanged 
after adjustment for sex, diabetes, hypertension, 
smoking, previous cardio vascular disease status, BMI, 
and renal function (adjusted ptrend=0·008 in 27 trials 
with individual participant data; p=0·012 after exclusion 
of four trials that exclusively included participants with 
heart failure or on dialysis). Nevertheless, there was 
still a significant reduction in major coronary events 
among all patients older than 75 years (figure 3). When 
we compared patients aged 75 years or younger with 
patients older than 75 years, we found no significant 
differences between the proportional effects on major 
coronary events, or on non-fatal myocardial infarctions 
and coronary deaths considered separately (with or 
without exclusion of the heart failure or dialysis trials; 
appendix).
Overall, we observed a 25% (RR 0·75, 95% CI 
0·73–0·78) proportional reduction in the risk of coronary 
revascularisation procedures with statin therapy or a 
more intensive statin regimen per 1·0 mmol/L lower 
LDL cholesterol, which did not differ significantly across 
age categories (ptrend=0·6), although we found no apparent 
effect on the relatively small number of procedures done 
among patients older than 75 years (figure 3; appendix). 
Similarly, the proportional reductions in stroke of 
any type (RR 0·84, 95% CI 0·80–0·89) did not differ 
significantly by age group (ptrend=0·7; figure 3).
Among participants with known vascular disease at 
study entry, proportional reductions in major vascular 
events were similar across age groups, regardless of 
whether heart failure and dialysis trials were included or 
excluded (ptrend=0·2 when these trials were included, 
ptrend=0·9 when these trials were excluded; figure 4; 
appendix). However, among participants with no history 
of vascular disease, we observed a significant trend 
towards smaller proportional risk reductions with 
increasing age (ptrend=0·05; figure 4), which persisted 
after exclusion of the heart failure and dialysis trials 
(ptrend=0·03; appendix).
Overall, we found a 12% (RR 0·88, 95% CI 0·85–0·91) 
proportional reduction in vascular mortality per 
1·0 mmol/L reduction in LDL cholesterol, with a trend 
towards smaller proportional reductions with older 
age (ptrend=0·004; figure 5). However, 1014 (53%) of 
1906 vascular deaths among people older than 75 years 
occurred in the four heart failure or dialysis trials. After 
exclusion of these trials, we observed no apparent trend 
towards smaller proportional reductions in vascular 
mortality with older age (ptrend=0·2, figure 5). We found 
no effect of statin therapy on all non-vascular causes of 
death (RR 0·96, 95% CI 0·92–1·01) irrespective of age 
group (ptrend=0·7; appendix). We also found no effects on 
deaths due to cancer or on the larger numbers of incident 
cancer cases, overall or by age (appendix). Consequently, 
when the beneficial effect on vascular mortality and 
the absence of effect on non-vascular mortality were 
combined, we observed a significant reduction in all-
cause mortality (RR 0·91, 95% CI 0·88–0.93; appendix). 
We also found a trend towards smaller proportional 
reductions in all-cause mortality with increasing age 
(ptrend=0·04; appendix), but this did not persist after 
exclusion of the heart failure and dialysis trials (ptrend=0·1, 
appendix).
Discussion
Individual randomised trials of statin therapy have 
previously reported significant cardiovascular risk re-
ductions among participants older than 65 years but 
younger than 70 years at the time of randomisation 
Figure 3: Effects on components of major vascular events per mmol/L reduction in LDL cholesterol in all 
studies, by age at randomisation
Data from participants with missing baseline data included in the totals. RR=rate ratio.
Events (% per annum) RR (CI) per 
1 mmol/L 
reduction in 
LDL cholesterol
Statin or 
more intensive
Control or 
less intensive
Major coronary event
≤55 years
>55 to ≤60 years
>60 to ≤65 years
>65 to ≤70 years
>70 to ≤75 years
>75 years
Total
Trend test χ21=6·92 (p=0·009)
Coronary revascularisation
≤55 years
>55 to ≤60 years
>60 to ≤65 years
>65 to ≤70 years
>70 to ≤75 years
>75 years
Total
Trend test χ21=0·33 (p=0·6)
Any stroke
≤55 years
>55 to ≤60 years
>60 to ≤65 years
>65 to ≤70 years
>70 to ≤75 years
>75 years
Total
Trend test χ21=0·17 (p=0·7)
 920 (1·1)
735 (1·1)
970 (1·2)
1066 (1·4)
1043 (1·9)
621 (2·6)
5355 (1·4)
1465 (1·7)
1013 (1·5)
1171 (1·4)
999 (1·3)
659 (1·2)
210 (0·9)
5517 (1·4)
245 (0·3)
287 (0·4)
462 (0·6)
 575 (0·7)
 579 (1·1)
 336 (1·4)
2484 (0·6)
1272 (1·5)
956 (1·4)
1294 (1·6)
1366 (1·8)
1225 (2·3)
713 (3·0)
6826 (1·7)
1865 (2·2)
1310 (1·9)
1397 (1·7)
1390 (1·8)
814 (1·5)
209 (0·9)
6985 (1·8)
 291 (0·3)
299 (0·4)
586 (0·7)
677 (0·9)
679 (1·3)
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(who were therefore aged >70–75 years at the end of a 
median of 5 years of scheduled treatment).26–30 Meta-
analyses among older people have consistently reported 
evidence for beneficial effects in secondary prevention, 
but the evidence has been less clear for primary 
prevention.31–34 Availability of in dividual participant data 
in the CTT Collaboration database has permitted more 
detailed assessment of the effects of statin therapy at 
different ages.
In our meta-analysis of data from 28 trials among 
186 854 people (with 14 483 [8%] older than 75 years at 
randomisation), we found slightly smaller proportional 
risk reductions in major vascular events (ptrend=0·06) 
and vascular deaths (ptrend=0·004) with increasing age. 
The exclusion criteria for 24 trials incorporated at least 
one of the following: a history of heart failure, poor 
ejection fraction, poor prognosis (other than from 
atherosclerotic disease), or the requirement for renal 
dialysis. However, two trials exclusively enrolled 
patients with moderate to severe (New York Heart 
Association Class II–IV) heart failure17,18 and two 
exclusively enrolled patients with end-stage renal 
disease requiring dialysis.19,20 Statin therapy has not 
been found to reduce the risk of major vascular events 
or vascular deaths in either of these patient popu-
lations,16–20 and consequently is not recommended for 
such patients in the absence of other indications.10,35,36 
Therefore, we did exploratory analyses that excluded 
these four trials17–20 to assess their contribution to the 
observed trends towards smaller relative reductions 
with increasing age. Among people without heart or 
renal failure, we found little evidence of any diminution 
of benefit with increasing age on major vascular events 
(ptrend=0·3) or on vascular death (ptrend=0·2).
Proportional reductions in major vascular events were 
similar irrespective of age among patients with a history 
of vascular disease (ie, secondary prevention), but 
we observed a trend towards smaller proportional risk 
reductions in those with no known vascular disease 
(ie, primary prevention), with no independently sig-
nificant reductions in either of the two age groups 
including patients older than 70 years. Among patients 
older than 70 years, only around a fifth of the major 
vascular events occurred in those with no history of 
vascular disease, and this relative paucity of evidence has 
led to further primary prevention trials among older 
individuals. For example, the STAREE trial37 aims to 
assess the effects of atorvastatin 40 mg daily in 
18 000 primary prevention patients aged 70 years or older 
at the time of recruitment.
We observed a trend towards smaller proportional 
reductions in major coronary events (ptrend=0·009) 
with inc reasing age, although a significant reduction 
remained among patients older than 75 years at ran-
domisation. The reasons underlying this trend are 
unclear. Age-related factors—such as altered pharma-
cokinetics and pharmacodynamics and an increased risk 
of drug inter actions in the setting of polypharmacy38—
would be expected to influence absolute LDL cholesterol 
reductions from therapy, but these did not differ 
materially by age. This trend might reflect a reduced 
capacity for statins to impact on advanced atherosclerotic 
plaques, greater diagnostic uncertainty at older ages 
(eg, difficulty separating myocardial infarctions due 
to unstable atherosclerosis from supply–demand im-
balances that occur with other illnesses), and poorer 
long-term adherence to the assigned study treatment 
among older people (since our weighted analyses are 
based on 1 year cholesterol differences). We observed no 
trends towards smaller proportional reductions in 
coronary revas cularisation procedures or strokes with 
increasing age, but too few such events occurred among 
patients older than 75 for us to assess the effects on these 
outcomes directly. Statin therapy definitely decreases the 
overall risk of ischaemic stroke and any stroke, but might 
increase the risk of haemorrhagic stroke.14 Individual 
participant data were not available from one eligible 
trial22 in which a large number of strokes (especially 
haemorrhagic) occurred, and we cannot reliably com-
ment on the relevance of age to the effects of statin 
therapy on stroke subtypes.
There is a paucity of information on the effects of 
statins on mortality in people at low risk of vascular 
Figure 4: Effects on major vascular events per mmol/L reduction in LDL cholesterol, subdivided by age at 
randomisation and by previous vascular disease
Data from participants with missing baseline data included in the totals. RR=rate ratio.
Events (% per annum) RR (CI) per 
1 mmol/L 
reduction in 
LDL cholesterol
Statin or 
more intensive
Control or 
less intensive
Participants without vascular disease
≤55 years
>55 to ≤60 years
>60 to ≤65 years
>65 to ≤70 years
>70 to ≤75 years
>75 years
Total
Trend test χ21=3·85 (p=0·05)
Participants with vascular disease
≤55 years
>55 to ≤60 years
>60 to ≤65 years
>65 to ≤70 years
>70 to ≤75 years
>75 years
Total
Trend test χ21=1·42 (p=0·2)
 290 (0·8)
 350 (1·0)
 416 (1·1)
 374 (1·2)
 400 (2·1)
 295 (2·7)
2125 (1·3)
1927 (4·0)
1391 (4·2)
1822 (4·4)
1889 (4·3)
1593 (4·8)
756 (6·0)
9378 (4·4)
  408 (1·2)
  415 (1·2)
  545 (1·5)
  581 (1·8)
  462 (2·4)
  308 (2·8)
 2719 (1·6)
2370 (5·1)
1692 (5·2)
2178 (5·3)
2286 (5·5)
1877 (5·8)
845 (6·8)
11 248 (5·4)
0·68 (0·56–0·83)
0·81 (0·67–0·99)
0·73 (0·61–0·87)
0·61 (0·51–0·73)
0·84 (0·70–1·01)
0·92 (0·73–1·16)
0·75 (0·71–0·80)
0·77 (0·71–0·83)
0·80 (0·73–0·88)
0·81 (0·75–0·88)
0·79 (0·73–0·86)
0·80 (0·73–0·88)
0·85 (0·73–0·98)
0·80 (0·77–0·82)
0·5
99% CI
0·75 1·51
95% CI
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disease, and very large trials (eg, the ongoing STAREE 
trial37) would be needed to provide direct evidence of a 
mortality reduction among older people in primary 
prevention. However, our overall analyses in a combined 
primary and secondary prevention population indicate 
that the proportional reductions in vascular mortality 
are similar irrespective of age. We have previously 
shown that statin therapy does not increase the 
incidence of cancer15 (as had been suggested8) or of non-
vascular causes of death.14 Consequently, given the 
similar proportional reductions in vascular mortality in 
both primary and secondary prevention settings, and 
the complete absence of effect of statin therapy on non-
vascular mortality, reductions in total mortality would 
be expected in both clinical settings.
Statins have been estimated to increase the risk of 
myopathy (defined as muscle pain or weakness 
combined with large increases in blood concentrations 
of creatine kinase) typically by one case per 10 000 patients 
treated with statins per year,9 but this risk can be 
increased by drug interactions and major comorbidities 
that are more common in older people.39 A 
meta-analysis40 of published data for participants older 
than 65 years at randomisation in statin trials reported 
no increased risk of less severe muscle-related adverse 
events. The CTT Collaboration is undertaking a 
prespecified analysis of reported adverse events in statin 
trials from original trial records,41 including examining 
whether age directly influences the small increase in 
risk of diabetes,42,43 and whether statins adversely 
influence cognition (noting that no excess risks have 
been identified in any large randomised trials29,30,44,45).
The selection criteria used among the 28 trials 
contributing to this meta-analysis, and differences in 
when they were conducted, mean that the absolute risk 
of major vascular events and mortality in our overall 
study population is not likely to be representative of any 
con temporary population. Therefore, we have not 
produced estimates of the absolute effects of statin 
therapy directly from the numbers of events observed 
in these trials. By contrast, the proportional effects 
observed in this meta-analysis are likely to be widely 
generalisable. Consequently, as the proportional reduc-
tions in major vascular events appeared to diminish 
only slightly (if at all) with increasing age, while 
untreated absolute risks of major vascular events in the 
general population increase exponentially with age, the 
absolute benefits of a given absolute reduction in LDL 
cholesterol with statin therapy would be expected to be 
substantially greater among older individuals. For 
example, in the primary prevention setting, two 
individuals aged 63 years and 78 years with otherwise 
identical risk factors might have projected major 
vascular event rates of 2·5% versus 4·0% per year, 
respectively. Reducing those risks by a fifth with a 
1·0 mmol/L LDL cholesterol reduction would prevent 
first major vascular events from occurring each year in 
50 individuals aged 63 years and 80 individuals aged 
78 years per 10 000 people treated.
In conclusion, statin therapy produces significant 
reductions in major vascular events, irrespective of age. 
There is less definitive direct evidence of benefit in the 
primary prevention setting among patients older than 
75 years, but evidence supports the use of statin therapy 
in older people considered to have a sufficiently high risk 
of occlusive vascular events.
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